Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation

Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines

“…In a recent study, Laban et al 31 examined the effects of combined administration of sorafenib and irradiation on 6 HNSCC cell lines. They found increased cellular radiosensitivity, which was not caused by an enhanced apoptotic rate or cell cycle effects but by sorafenib inducedblockade of DNA double-strand breaks.…”

Molecular targeting in combination with platinum‐based chemoradiotherapy in head and neck cancer treatment

“…Several other drugs are currently under preclinical investigation in the hopes of their improving CRT outcomes. We have been able to demonstrate that the small molecule inhibitor sorafenib (Nexavar; Bayer, Leverkusen, Germany) leads to radiosensitization in HPV‐negative HNSCC cell lines and also sensitizes these cells toward CDDP (unpublished data from the authors of the present review article). As these effects seem to be mediated mainly by the inhibition of DNA double‐strand break repair, an important factor influencing cell survival after ionizing radiation and CDDP, sorafenib seems to be a promising targeted therapeutic agent for combination with CRT worthy of being investigated in further preclinical studies.…”

Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era

“…[37][38][39] Sorafenib has a synergistic effect with ionizing radiation in a variety of tumor cell lines. [40][41][42][43] The induction of autophagy, which can be induced by temsirolimus, has been shown to be synergistic with radiation in RCC cell lines. 44 However, this report suggests that KI therapy does not significantly affect survival or brain tumor control outcomes, arguing against a synergistic effect of KIs with radiotherapy on brain metastases from RCC.…”